Results 221 to 230 of about 274,076 (393)

Semi‐mechanistic population PK/PD model to aid clinical understanding of myelodysplastic syndromes following treatment with Venetoclax and Azacitidine

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 448-459, March 2025.
Abstract Myelodysplastic syndromes (MDS) represent a group of bone marrow disorders involving cytopenias, hypercellular bone marrow, and dysplastic hematopoietic progenitors. MDS remains a challenge to treat due to the complex interplay between disease‐induced and treatment‐related cytopenias.
Neha Thakre, Corinna Maier, Jiuhong Zha, Benjamin Engelhardt, Johannes E. Wolff, Sven Mensing   +5 more
wiley   +1 more source

Diagnosis and management of neutropenia. [PDF]

Blood Res
Min KI, Byeon S.
europepmc   +1 more source

894 AUTOIMMUNE NEUTROPENIA: ASSOCIATION WITH LOW IgG2 DECREASED NATURAL KILLER ACTIVITY [PDF]

, 1985
James B. Bussel, Margaret W. Hilgartner, Parviz Lalezari, Senih Fikrig, Patricia A Fitzerald   +4 more
openalex   +1 more source

Chronic Neutropenia [PDF]

Archives of Disease in Childhood, 1957
openaire   +2 more sources

G-CSF and GM-CSF in Neutropenia

Journal of Immunology, 2015
Hrishikesh M. Mehta, M. Malandra, S. Corey   +2 more
semanticscholar   +1 more source

Role of neutrophils granularity intensity and reactive lymphocytes in assessing changes in lupus activity

Rheumatology &Autoimmunity, EarlyView.
Neut‐GI and Re‐Lymp levels correlated with changes in SLEDAl‐2K scores. Specifically, increasing in SLEDAl‐2K scores was associated with decreasing in extended inflammatory parameters. Thus, Neut‐Gland Re‐Lymp might serve as simpler and more cost‐effective alternatives to SLEDAI‐2K scores for monitoring changes in SLE activity.
Galuh Setyorini, Laniyati Hamijoyo, Evan Susandi, Delita Prihatni, Andri Iskandar Mardia, Amaylia Oehadian   +5 more
wiley   +1 more source

Expanding the phenotypic and genetic landscape of congenital neutropenia through whole-exome and genome sequencing. [PDF]

Hemasphere
Marti S, Pellet P, Beaupain B, Durix L, Buratti J, Réguerre Y, Aladjidi N, Azarnoush S, Clauin S, Chahla WA, Blaison G, Bertand J, Bodet D, Brethon B, Chane-Teng J, Delafoy M, Dupraz C, Gandemer V, Denizeau P, Goldenberg A, Hirsch P, l'Haridon A, Marie-Cardine A, Vera G, Nelken B, Nizery L, Nolla M, Pasquet M, Rosain J, Terriou L, Plo I, Donadieu J, Bellanné-Chantelot C.   +32 more
europepmc   +1 more source

MANAGEMENT OF FEVER/NEUTROPENIA (F/N) IN CHILDREN WITH CANCER: A NATIONAL SURVEY [PDF]

, 1987
Linda P. Miller, Denis R. Miller
openalex   +1 more source

Neutropenia and metolazone. [PDF]

BMJ, 1989
openaire   +3 more sources

Nanoparticle Therapeutics in Clinical Perspective: Classification, Marketed Products, and Regulatory Landscape

Small, EarlyView.
This review presents a detailed overview of clinically approved nanoparticle therapeutics, classifying them by type and discussing their unique advantages in drug delivery. It highlights regulatory challenges across global markets and emphasizes the need for adaptive approval pathways.
Nimeet Desai, Dhwani Rana, Mitali Patel, Neha Bajwa, Rajendra Prasad, Lalitkumar K. Vora   +5 more
wiley   +1 more source